Ampersand Capital Partners Acquires Specac Ltd.

Specac, Ltd Acquires Harrick Scientific, Inc

April 2, 2024

Manufacturing

Specac, Ltd — a portfolio company of Ampersand Capital Partners — has acquired Harrick Scientific, a U.S.-based manufacturer of spectroscopy accessories and optical components. The deal combines complementary product lines to create a broader life-sciences-oriented platform serving OEM and laboratory end markets and will be supported by Ampersand operating resources on the Specac board and management team.

Ampersand Capital Partners Acquires CurTec

July 21, 2025

Packaging

Ampersand Capital Partners has acquired CurTec Group B.V., a Netherlands-based manufacturer of high-performance plastic packaging for pharmaceutical and specialty chemical applications, from Bencis Capital Partners in partnership with CurTec management. The deal positions Ampersand to scale CurTec's U.S. footprint, accelerate product innovation, and expand capacity and commercial capabilities to serve pharma and specialty chemicals customers globally.

Ampersand Capital Partners Invests in Syft Technologies

April 18, 2022

Manufacturing

Ampersand Capital Partners made a minority growth equity investment in Syft Technologies Limited to accelerate the company's progress in the semiconductor market and develop scalable opportunities in life sciences. The investment will also bring Ampersand partner David Patteson to Syft’s board to support commercial growth and scale-up.

Ampersand Capital Partners Majority Recapitalizes New England Peptide

October 7, 2019

Biotechnology

Ampersand Capital Partners completed a majority recapitalization of New England Peptide to support the company's worldwide growth initiatives and expand its peptide synthesis capabilities. As part of the transaction, Dr. José de Chastonay was appointed Executive Chairman; founders Sam and Jennifer Massoni remain noted in the announcement.

Ampersand Capital Partners Acquires Peptides International and Merges It with New England Peptide

December 16, 2019

Biotechnology

Ampersand Capital Partners has acquired Peptides International and merged it into its existing portfolio company, New England Peptide, creating a combined provider of custom and catalog peptide synthesis services. The transaction is an add-on to Ampersand’s New England Peptide platform to expand scale, capabilities, and customer relationships across pharmaceutical, biotech and academic markets.

Ampersand Capital Partners Recapitalizes American Laboratory Products Company (ALPCO)

September 21, 2020

Medical Devices

Ampersand Capital Partners completed a majority recapitalization of American Laboratory Products Company (ALPCO) to provide growth capital for expanding ALPCO's diagnostics test kit offering, geographic reach, and R&D/production capabilities. Founders Richard and Jan Conley will remain shareholders, Sean Conley will continue as CEO, and Larry McCarthy, PhD was named Board Chairman.